Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

NCT02848313 is registered in ClinicalTrials.gov with Stealth BioTherapeutics Inc. as lead sponsor.

NCT NCT02848313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02848313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Lead sponsor
Stealth BioTherapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 28, 2016
Completion date
April 10, 2018
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration